{
  "meta": {
    "description": "Enhanced Oncology Knowledge Graph with comprehensive molecular mechanisms, clinical data, and therapeutic information",
    "version": "2.0",
    "last_updated": "2025-10-22",
    "data_sources": [
      "TCGA", "cBioPortal", "OncoKB", "ClinVar", "DrugBank", "KEGG", "Reactome", "UniProt"
    ]
  },
  "nodes": [
    {
      "id": "disease:Lung Cancer",
      "label": "Lung Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["lung", "NSCLC", "SCLC", "pulmonary carcinoma"],
        "description": "Malignant tumor arising from lung epithelial cells",
        "subtypes": [
          {
            "name": "Non-Small Cell Lung Cancer (NSCLC)",
            "frequency": "85%",
            "subtypes": ["Adenocarcinoma (40%)", "Squamous Cell Carcinoma (25%)", "Large Cell Carcinoma (10%)"]
          },
          {
            "name": "Small Cell Lung Cancer (SCLC)",
            "frequency": "15%",
            "characteristics": "Highly aggressive, rapid doubling time"
          }
        ],
        "epidemiology": {
          "incidence": "2.2 million new cases/year globally",
          "mortality": "Leading cause of cancer death worldwide",
          "5_year_survival": "18.6%"
        },
        "risk_factors": ["Smoking (85%)", "Radon exposure", "Asbestos", "Air pollution"],
        "staging": ["Stage I-IV", "TNM classification"],
        "molecular_alterations": {
          "EGFR_mutations": "15-20% in adenocarcinoma",
          "KRAS_mutations": "25-30%",
          "ALK_fusions": "3-5%",
          "ROS1_fusions": "1-2%",
          "BRAF_mutations": "2-3%"
        }
      }
    },
    {
      "id": "disease:Breast Cancer",
      "label": "Breast Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["breast", "mammary carcinoma"],
        "description": "Malignant tumor originating in breast tissue",
        "subtypes": [
          {
            "name": "Hormone Receptor Positive (HR+)",
            "frequency": "70%",
            "description": "Express estrogen and/or progesterone receptors"
          },
          {
            "name": "HER2 Positive",
            "frequency": "15-20%",
            "description": "Overexpress HER2/ERBB2 protein"
          },
          {
            "name": "Triple Negative (TNBC)",
            "frequency": "15%",
            "description": "Lack ER, PR, and HER2 expression"
          }
        ],
        "epidemiology": {
          "incidence": "2.3 million new cases/year globally",
          "mortality": "Second leading cause of cancer death in women",
          "5_year_survival": "90% (localized), 85% (regional), 28% (distant)"
        },
        "molecular_alterations": {
          "PIK3CA_mutations": "40%",
          "TP53_mutations": "30%",
          "BRCA1_mutations": "5-10% hereditary",
          "BRCA2_mutations": "5-10% hereditary",
          "HER2_amplification": "15-20%"
        },
        "biomarkers": ["ER", "PR", "HER2", "Ki-67", "PD-L1"]
      }
    },
    {
      "id": "disease:Colorectal Cancer",
      "label": "Colorectal Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["colorectal", "colon cancer", "rectal cancer", "CRC"],
        "description": "Malignant tumor arising from colon or rectal epithelium",
        "pathogenesis": "Adenoma-carcinoma sequence: Normal epithelium → Adenoma → Carcinoma",
        "molecular_pathways": [
          {
            "name": "Chromosomal Instability (CIN)",
            "frequency": "85%",
            "key_alterations": ["APC", "KRAS", "PIK3CA", "TP53"]
          },
          {
            "name": "Microsatellite Instability (MSI)",
            "frequency": "15%",
            "key_alterations": ["MLH1", "MSH2", "MSH6", "PMS2"]
          }
        ],
        "epidemiology": {
          "incidence": "1.9 million new cases/year globally",
          "mortality": "Third leading cause of cancer death",
          "5_year_survival": "90% (Stage I), 71% (Stage III), 14% (Stage IV)"
        },
        "molecular_alterations": {
          "APC_mutations": "80%",
          "KRAS_mutations": "40%",
          "PIK3CA_mutations": "20%",
          "TP53_mutations": "60%",
          "BRAF_mutations": "10%"
        }
      }
    },
    {
      "id": "gene:EGFR",
      "label": "EGFR",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Epidermal Growth Factor Receptor",
        "chromosome": "7p11.2",
        "protein_class": "Receptor tyrosine kinase",
        "structure": {
          "domains": [
            "Extracellular ligand-binding domain (domains I-IV)",
            "Transmembrane domain",
            "Intracellular tyrosine kinase domain",
            "C-terminal regulatory domain"
          ],
          "size": "1210 amino acids",
          "molecular_weight": "134 kDa"
        },
        "function": "Cell surface receptor that binds EGF family ligands, undergoes dimerization and autophosphorylation, activating downstream PI3K/AKT and RAS/MAPK pathways",
        "ligands": ["EGF", "TGF-α", "Amphiregulin", "Betacellulin", "Epiregulin"],
        "clinical_significance": {
          "lung_cancer": {
            "mutation_frequency": "15-20% in adenocarcinoma",
            "common_mutations": [
              {
                "name": "L858R",
                "frequency": "45%",
                "location": "Exon 21",
                "effect": "Increased kinase activity"
              },
              {
                "name": "Exon 19 deletions",
                "frequency": "45%",
                "effect": "Constitutive activation"
              },
              {
                "name": "T790M",
                "frequency": "50% of resistant cases",
                "location": "Exon 20",
                "effect": "Resistance to 1st/2nd gen TKIs"
              }
            ]
          },
          "other_cancers": {
            "overexpression": "Glioblastoma (40%), Head/Neck (90%), Colorectal (25-77%)"
          }
        },
        "therapeutic_targets": ["Osimertinib", "Gefitinib", "Erlotinib", "Afatinib", "Cetuximab"],
        "pathways": ["PI3K/AKT/mTOR", "RAS/MAPK", "JAK/STAT", "PLCγ"]
      }
    },
    {
      "id": "gene:KRAS",
      "label": "KRAS",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Kirsten Rat Sarcoma Viral Oncogene Homolog",
        "chromosome": "12p12.1",
        "protein_class": "Small GTPase",
        "structure": {
          "domains": [
            "G domain (GTPase domain)",
            "Hypervariable region",
            "CAAX motif for membrane localization"
          ],
          "size": "189 amino acids",
          "molecular_weight": "21 kDa"
        },
        "function": "Molecular switch cycling between GTP-bound (active) and GDP-bound (inactive) states, regulating cell proliferation, differentiation, and apoptosis",
        "mechanism": "Activated by growth factor receptors via GEFs (e.g., SOS), inactivated by GAPs (e.g., NF1)",
        "clinical_significance": {
          "pan_cancer": {
            "mutation_frequency": "30% across all cancers",
            "hotspot_codons": [
              {
                "codon": "G12",
                "frequency": "80%",
                "common_variants": ["G12D", "G12V", "G12C"],
                "effect": "Impaired GTPase activity"
              },
              {
                "codon": "G13",
                "frequency": "15%",
                "common_variant": "G13D",
                "effect": "Reduced GAP sensitivity"
              },
              {
                "codon": "Q61",
                "frequency": "5%",
                "common_variants": ["Q61H", "Q61L", "Q61R"],
                "effect": "Constitutive activation"
              }
            ]
          },
          "cancer_specific": {
            "pancreatic": "95%",
            "colorectal": "40%",
            "lung_adenocarcinoma": "25%",
            "endometrial": "15-30%"
          }
        },
        "drug_resistance": {
          "EGFR_inhibitors": "Predictive biomarker for resistance in colorectal cancer",
          "cetuximab_resistance": "KRAS mutations confer primary resistance"
        },
        "therapeutic_targets": ["Sotorasib (G12C)", "Adagrasib (G12C)", "MRTX1133 (G12D)"],
        "pathways": ["MAPK/ERK", "PI3K/AKT", "RAL-GEF"]
      }
    },
    {
      "id": "gene:TP53",
      "label": "TP53",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Tumor Protein p53",
        "chromosome": "17p13.1",
        "protein_class": "Transcription factor/Tumor suppressor",
        "nickname": "Guardian of the genome",
        "structure": {
          "domains": [
            "N-terminal transactivation domain",
            "Proline-rich domain",
            "DNA-binding domain (core domain)",
            "Tetramerization domain",
            "C-terminal regulatory domain"
          ],
          "size": "393 amino acids",
          "molecular_weight": "43 kDa"
        },
        "function": "Master regulator responding to DNA damage, oncogene activation, and cellular stress by inducing cell cycle arrest, DNA repair, or apoptosis",
        "mechanism": {
          "activation": "Post-translational modifications (phosphorylation, acetylation) in response to stress",
          "target_genes": ["p21 (CDKN1A)", "BAX", "PUMA", "MDM2", "GADD45"],
          "outcomes": ["G1/S checkpoint arrest", "Apoptosis", "Senescence", "DNA repair"]
        },
        "clinical_significance": {
          "mutation_frequency": "50% across all cancers",
          "li_fraumeni_syndrome": "Germline mutations cause hereditary cancer predisposition",
          "cancer_specific": {
            "ovarian": "95%",
            "colorectal": "60%",
            "lung": "50%",
            "breast": "30%",
            "glioblastoma": "25%"
          },
          "hotspot_mutations": [
            {
              "residue": "R175H",
              "frequency": "5%",
              "effect": "Loss of DNA-binding activity"
            },
            {
              "residue": "R248Q/W",
              "frequency": "4%",
              "effect": "Conformational change"
            },
            {
              "residue": "R273H/C",
              "frequency": "4%",
              "effect": "Contact mutation"
            }
          ]
        },
        "therapeutic_implications": {
          "wild_type": "Sensitive to MDM2 inhibitors, DNA-damaging agents",
          "mutant": "Potential targets: p53 reactivators, synthetic lethal approaches"
        },
        "pathways": ["DNA damage response", "Cell cycle control", "Apoptosis", "Autophagy"]
      }
    },
    {
      "id": "gene:BRCA1",
      "label": "BRCA1",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Breast Cancer 1, Early Onset",
        "chromosome": "17q21.31",
        "protein_class": "Tumor suppressor/DNA repair protein",
        "structure": {
          "domains": [
            "RING finger domain (E3 ubiquitin ligase)",
            "Coiled-coil domain",
            "BRCT domains (2x) - protein interaction"
          ],
          "size": "1863 amino acids",
          "molecular_weight": "208 kDa"
        },
        "function": "Key component of homologous recombination DNA repair pathway, cell cycle checkpoint control, and transcriptional regulation",
        "mechanism": {
          "dna_repair": "Forms BRCA1-associated genome surveillance complex (BASC)",
          "interactions": ["BRCA2", "RAD51", "PALB2", "53BP1", "ATM", "CHK2"],
          "cell_cycle": "G2/M checkpoint regulation"
        },
        "clinical_significance": {
          "hereditary_cancer": {
            "breast_cancer_risk": "55-72% lifetime risk",
            "ovarian_cancer_risk": "39-44% lifetime risk",
            "prostate_cancer_risk": "Increased risk in men",
            "penetrance": "Age-dependent, modifier genes influence risk"
          },
          "mutation_types": [
            {
              "type": "Frameshift",
              "frequency": "60%",
              "effect": "Truncated protein"
            },
            {
              "type": "Nonsense",
              "frequency": "25%",
              "effect": "Premature stop codon"
            },
            {
              "type": "Large rearrangements",
              "frequency": "10%",
              "effect": "Exon deletions/duplications"
            }
          ],
          "founder_mutations": {
            "185delAG": "Ashkenazi Jewish population",
            "5382insC": "Eastern European",
            "C61G": "Norwegian"
          }
        },
        "therapeutic_implications": {
          "parp_inhibitors": "Synthetic lethality in BRCA1-deficient tumors",
          "platinum_sensitivity": "Enhanced response to DNA cross-linking agents",
          "immunotherapy": "HRD tumors show increased neoantigen burden"
        },
        "biomarkers": ["HRD score", "Genomic LOH", "Platinum sensitivity"],
        "pathways": ["Homologous recombination", "NHEJ", "Cell cycle checkpoints", "Fanconi anemia pathway"]
      }
    },
    {
      "id": "gene:HER2",
      "label": "HER2",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Human Epidermal Growth Factor Receptor 2",
        "official_name": "ERBB2",
        "chromosome": "17q12",
        "protein_class": "Receptor tyrosine kinase",
        "structure": {
          "domains": [
            "Extracellular domain (ECD)",
            "Transmembrane domain",
            "Intracellular tyrosine kinase domain"
          ],
          "size": "1255 amino acids",
          "molecular_weight": "138 kDa"
        },
        "function": "Member of EGFR family, forms heterodimers with other ERBB receptors, lacks high-affinity ligand binding but serves as preferred dimerization partner",
        "mechanism": {
          "activation": "Ligand-independent dimerization, transphosphorylation",
          "signaling": "PI3K/AKT and MAPK pathway activation",
          "cellular_effects": "Proliferation, survival, invasion, angiogenesis"
        },
        "clinical_significance": {
          "breast_cancer": {
            "amplification_frequency": "15-20%",
            "assessment": "IHC (0, 1+, 2+, 3+) and FISH confirmation",
            "prognosis": "Historically poor, improved with targeted therapy"
          },
          "gastric_cancer": {
            "amplification_frequency": "10-15%",
            "therapeutic_target": "Trastuzumab approved"
          },
          "other_cancers": "Bladder, endometrial, salivary gland"
        },
        "therapeutic_targets": {
          "monoclonal_antibodies": [
            {
              "drug": "Trastuzumab",
              "mechanism": "ECD binding, ADCC, inhibits dimerization",
              "approval": "1998 (metastatic), 2006 (adjuvant)"
            },
            {
              "drug": "Pertuzumab",
              "mechanism": "Prevents HER2-HER3 dimerization",
              "combination": "With trastuzumab (dual blockade)"
            }
          ],
          "tyrosine_kinase_inhibitors": [
            {
              "drug": "Lapatinib",
              "mechanism": "Reversible dual EGFR/HER2 inhibitor",
              "indication": "Brain metastases, trastuzumab resistance"
            },
            {
              "drug": "Neratinib",
              "mechanism": "Irreversible pan-HER inhibitor",
              "indication": "Extended adjuvant therapy"
            }
          ],
          "antibody_drug_conjugates": [
            {
              "drug": "Trastuzumab emtansine (T-DM1)",
              "mechanism": "Targeted delivery of cytotoxic payload",
              "indication": "Resistant/recurrent disease"
            }
          ]
        },
        "resistance_mechanisms": [
          "PI3K/AKT activation",
          "Alternative receptor signaling",
          "Immune evasion",
          "Tumor heterogeneity"
        ],
        "pathways": ["PI3K/AKT/mTOR", "MAPK/ERK", "JAK/STAT", "PLCγ/PKC"]
      }
    },
    {
      "id": "drug:Trastuzumab",
      "label": "Trastuzumab",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "brand_names": ["Herceptin", "Ogivri", "Herzuma"],
        "drug_class": "Monoclonal antibody",
        "molecular_target": "HER2/ERBB2 extracellular domain",
        "mechanism_of_action": {
          "primary": "Binds to domain IV of HER2 extracellular region",
          "effects": [
            "Inhibits HER2 homodimerization and heterodimerization",
            "Induces antibody-dependent cellular cytotoxicity (ADCC)",
            "Inhibits PI3K/AKT signaling",
            "Reduces angiogenesis",
            "Induces cell cycle arrest"
          ]
        },
        "pharmacology": {
          "half_life": "28.5 days",
          "administration": "IV infusion",
          "metabolism": "Proteolytic degradation",
          "distribution": "Limited extravascular distribution"
        },
        "clinical_applications": {
          "breast_cancer": {
            "indications": [
              "HER2+ metastatic breast cancer",
              "HER2+ early-stage breast cancer (adjuvant)",
              "HER2+ neoadjuvant therapy"
            ],
            "efficacy": "50% reduction in recurrence risk (adjuvant)",
            "combinations": ["Chemotherapy", "Pertuzumab", "CDK4/6 inhibitors"]
          },
          "gastric_cancer": {
            "indication": "HER2+ advanced gastric/GEJ adenocarcinoma",
            "combination": "With chemotherapy (first-line)"
          }
        },
        "adverse_effects": {
          "cardiotoxicity": {
            "frequency": "2-7%",
            "mechanism": "HER2 role in cardiomyocyte survival",
            "monitoring": "ECHO/MUGA every 3 months",
            "reversibility": "Usually reversible upon discontinuation"
          },
          "infusion_reactions": "40% (mostly grade 1-2)",
          "pulmonary_toxicity": "Rare (<1%)"
        },
        "resistance_mechanisms": [
          "PI3K pathway activation",
          "Insulin-like growth factor-1 receptor (IGF-1R) upregulation",
          "HER family receptor crosstalk",
          "Loss of PTEN tumor suppressor"
        ],
        "biomarkers": {
          "predictive": "HER2 amplification/overexpression (IHC 3+ or FISH+)",
          "resistance": "PIK3CA mutations, PTEN loss"
        },
        "approval_history": {
          "fda_approval": "1998 (metastatic), 2006 (adjuvant)",
          "breakthrough_drug": "First targeted therapy for breast cancer"
        }
      }
    },
    {
      "id": "drug:Osimertinib",
      "label": "Osimertinib",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "brand_name": "Tagrisso",
        "drug_class": "Third-generation EGFR tyrosine kinase inhibitor",
        "molecular_target": "EGFR with T790M resistance mutation",
        "mechanism_of_action": {
          "primary": "Irreversible inhibition of EGFR kinase domain",
          "selectivity": [
            "Active against sensitizing mutations (L858R, exon 19 del)",
            "Overcomes T790M resistance mutation",
            "Wild-type EGFR sparing at therapeutic doses"
          ],
          "binding": "Covalent binding to Cys797 in ATP-binding pocket"
        },
        "pharmacology": {
          "half_life": "48 hours",
          "bioavailability": "Good oral absorption",
          "metabolism": "CYP3A4, CYP3A5",
          "cns_penetration": "Excellent (crosses blood-brain barrier)"
        },
        "clinical_applications": {
          "nsclc": {
            "first_line": "EGFR-mutated advanced NSCLC",
            "second_line": "T790M-positive NSCLC after 1st/2nd gen TKI progression",
            "efficacy": "PFS 18.9 months vs 10.2 months (erlotinib) in 1st line"
          },
          "brain_metastases": "Superior CNS activity vs other EGFR TKIs"
        },
        "resistance_mutations": [
          {
            "mutation": "C797S",
            "mechanism": "Prevents covalent binding",
            "frequency": "15-20% of resistant cases"
          },
          {
            "mutation": "G796S/D/R",
            "mechanism": "Steric hindrance",
            "frequency": "5-10%"
          }
        ],
        "adverse_effects": {
          "common": [
            "Diarrhea (58%)",
            "Rash (34%)",
            "Dry skin (23%)",
            "Nail toxicity (22%)"
          ],
          "serious": [
            "Interstitial lung disease (3.3%)",
            "QTc prolongation (0.9%)",
            "Cardiomyopathy (rare)"
          ]
        },
        "biomarkers": {
          "predictive": [
            "EGFR L858R mutation",
            "EGFR exon 19 deletion",
            "EGFR T790M mutation"
          ],
          "resistance": "Liquid biopsy for resistance mutations"
        },
        "approval_history": {
          "fda_approval": "2015 (T790M+), 2018 (1st line)",
          "designation": "Breakthrough therapy, priority review"
        }
      }
    },
    {
      "id": "pathway:PI3K-AKT-mTOR",
      "label": "PI3K-AKT-mTOR Pathway",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "full_name": "Phosphoinositide 3-kinase/Protein Kinase B/Mechanistic Target of Rapamycin",
        "function": "Master regulator of cell survival, growth, proliferation, and metabolism",
        "components": {
          "pi3k": {
            "classes": ["Class I (PI3Kα, β, γ, δ)", "Class II", "Class III"],
            "regulation": "Activated by RTKs, RAS, cytokines",
            "function": "Phosphorylates PIP2 to generate PIP3"
          },
          "akt": {
            "isoforms": ["AKT1 (PKBα)", "AKT2 (PKBβ)", "AKT3 (PKBγ)"],
            "activation": "PDK1 and mTORC2-mediated phosphorylation",
            "substrates": ["mTOR", "GSK3β", "FOXO", "BAD", "MDM2"]
          },
          "mtor": {
            "complexes": [
              {
                "name": "mTORC1",
                "components": ["mTOR", "Raptor", "mLST8", "PRAS40", "Deptor"],
                "functions": ["Protein synthesis", "Lipid synthesis", "Autophagy inhibition"]
              },
              {
                "name": "mTORC2",
                "components": ["mTOR", "Rictor", "mLST8", "mSin1", "Protor"],
                "functions": ["AKT activation", "Cytoskeletal organization"]
              }
            ]
          }
        },
        "regulation": {
          "positive": ["Growth factors", "Nutrients", "Energy status"],
          "negative": ["PTEN", "TSC1/2", "LKB1/AMPK", "p53"]
        },
        "cellular_functions": [
          "Cell survival and apoptosis resistance",
          "Protein synthesis and ribosome biogenesis",
          "Glucose metabolism and glycolysis",
          "Lipid synthesis",
          "Cell cycle progression",
          "Autophagy regulation",
          "Angiogenesis"
        ],
        "cancer_relevance": {
          "alterations": [
            "PIK3CA mutations (40% breast cancer)",
            "PTEN loss (30-50% various cancers)",
            "AKT amplification",
            "mTOR mutations (rare)"
          ],
          "therapeutic_targets": [
            "PI3K inhibitors (Alpelisib)",
            "AKT inhibitors (Capivasertib)",
            "mTOR inhibitors (Everolimus, Temsirolimus)",
            "Dual PI3K/mTOR inhibitors"
          ]
        },
        "clinical_significance": {
          "drug_resistance": "Common resistance mechanism to targeted therapies",
          "biomarkers": ["PIK3CA mutations", "PTEN expression", "p-AKT levels"],
          "combination_therapy": "Rationale for combining with other targeted agents"
        }
      }
    },
    {
      "id": "pathway:RAS-MAPK",
      "label": "RAS-MAPK Pathway",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "full_name": "RAS-Mitogen-Activated Protein Kinase Pathway",
        "function": "Transmits signals from cell surface to nucleus controlling proliferation, differentiation, and survival",
        "components": {
          "ras_proteins": [
            "KRAS (most frequently mutated in cancer)",
            "NRAS",
            "HRAS"
          ],
          "raf_kinases": [
            "BRAF (most active)",
            "CRAF (RAF1)",
            "ARAF"
          ],
          "mek_kinases": ["MEK1", "MEK2"],
          "erk_kinases": ["ERK1", "ERK2"]
        },
        "mechanism": {
          "activation": "RTK → GRB2/SOS → RAS-GTP → RAF → MEK → ERK",
          "nuclear_translocation": "Active ERK translocates to nucleus",
          "transcriptional_targets": ["FOS", "JUN", "MYC", "CCND1"]
        },
        "regulation": {
          "positive": ["Growth factors", "Cytokines", "Stress signals"],
          "negative": ["DUSP phosphatases", "SPRY proteins", "NF1 (RAS-GAP)"],
          "feedback": "ERK-mediated negative feedback on RAS/RAF"
        },
        "cellular_functions": [
          "Cell cycle progression (G1/S transition)",
          "Cell proliferation",
          "Differentiation",
          "Migration and invasion",
          "Angiogenesis",
          "Apoptosis resistance"
        ],
        "cancer_relevance": {
          "mutation_frequency": "30% of all cancers have RAS mutations",
          "cancer_specific": {
            "pancreatic": "KRAS mutations in 95%",
            "colorectal": "KRAS/BRAF mutations in 50%",
            "melanoma": "BRAF mutations in 50%",
            "lung": "KRAS mutations in 25%"
          },
          "therapeutic_targets": [
            "MEK inhibitors (Trametinib, Cobimetinib)",
            "BRAF inhibitors (Vemurafenib, Dabrafenib)",
            "ERK inhibitors (Ulixertinib)",
            "KRAS G12C inhibitors (Sotorasib, Adagrasib)"
          ]
        },
        "resistance_mechanisms": [
          "Reactivation of MAPK signaling",
          "PI3K/AKT pathway activation",
          "Receptor tyrosine kinase upregulation",
          "Cell cycle checkpoint bypass"
        ],
        "biomarkers": [
          "RAS mutation status",
          "BRAF mutation status",
          "p-ERK levels",
          "DUSP expression"
        ]
      }
    },
    {
      "id": "biomarker:PD-L1",
      "label": "PD-L1",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "full_name": "Programmed Death-Ligand 1",
        "official_name": "CD274",
        "protein_class": "Immune checkpoint molecule",
        "function": "Transmembrane protein that serves as a ligand for PD-1 receptor, mediating immune suppression",
        "mechanism": {
          "expression": "Induced by interferon-γ, oncogenic signaling, hypoxia",
          "interaction": "Binds to PD-1 on T cells and B7.1 on APCs",
          "effect": "Inhibits T cell activation, promotes T cell exhaustion"
        },
        "clinical_significance": {
          "biomarker_role": "Predictive biomarker for immune checkpoint inhibitor response",
          "assessment_methods": [
            {
              "assay": "22C3 pharmDx",
              "indication": "Pembrolizumab companion diagnostic",
              "scoring": "TPS (Tumor Proportion Score)"
            },
            {
              "assay": "28-8 pharmDx",
              "indication": "Nivolumab complementary diagnostic",
              "scoring": "Tumor cell and immune cell staining"
            },
            {
              "assay": "SP142",
              "indication": "Atezolizumab companion diagnostic",
              "scoring": "IC (Immune Cell) scoring system"
            }
          ],
          "cutoff_values": {
            "high_expression": "≥50% TPS",
            "positive_expression": "≥1% TPS",
            "interpretation": "Higher expression correlates with better ICI response"
          }
        },
        "cancer_expression": {
          "high_frequency": ["Hodgkin lymphoma (95%)", "Head/neck SCC (60%)", "Bladder cancer (40%)"],
          "moderate_frequency": ["NSCLC (30%)", "Renal cell carcinoma (25%)"],
          "low_frequency": ["Breast cancer (15%)", "Colorectal cancer (5%)"]
        },
        "therapeutic_implications": {
          "checkpoint_inhibitors": [
            "Pembrolizumab (anti-PD-1)",
            "Nivolumab (anti-PD-1)",
            "Atezolizumab (anti-PD-L1)",
            "Durvalumab (anti-PD-L1)"
          ],
          "combination_strategies": [
            "PD-1/PD-L1 + CTLA-4 inhibitors",
            "PD-1/PD-L1 + chemotherapy",
            "PD-1/PD-L1 + targeted therapy"
          ]
        },
        "limitations": {
          "heterogeneity": "Spatial and temporal variation in expression",
          "assay_differences": "Different antibodies and scoring systems",
          "false_negatives": "Some PD-L1 negative tumors respond to ICIs"
        },
        "emerging_biomarkers": [
          "Tumor mutational burden (TMB)",
          "Microsatellite instability (MSI)",
          "T cell infiltration",
          "Interferon-γ signature"
        ]
      }
    },
    {
      "id": "biomarker:CEA",
      "label": "CEA",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "full_name": "Carcinoembryonic Antigen",
        "protein_class": "Glycoprotein",
        "normal_function": "Cell adhesion molecule, expressed during fetal development",
        "clinical_applications": {
          "colorectal_cancer": {
            "monitoring": "Post-treatment surveillance and recurrence detection",
            "prognostic": "Elevated levels associated with advanced stage and poor prognosis",
            "normal_range": "<5 ng/mL in non-smokers, <10 ng/mL in smokers",
            "sensitivity": "70-80% in metastatic disease",
            "specificity": "Limited due to elevation in benign conditions"
          },
          "other_cancers": [
            "Pancreatic cancer",
            "Gastric cancer", 
            "Lung cancer",
            "Breast cancer",
            "Ovarian cancer"
          ]
        },
        "limitations": {
          "screening": "Not recommended for cancer screening due to low specificity",
          "early_detection": "Often normal in early-stage disease",
          "false_positives": "Elevated in smokers, inflammatory conditions, liver disease"
        },
        "clinical_utility": {
          "baseline_measurement": "Before treatment initiation",
          "monitoring_frequency": "Every 3-6 months post-treatment",
          "rising_levels": "May indicate recurrence before imaging detection",
          "half_life": "2-8 days"
        },
        "guidelines": {
          "asco_recommendations": "Routine monitoring not recommended without clinical indication",
          "nccn_guidelines": "Optional for surveillance in high-risk patients"
        }
      }
    }
  ],
  "edges": [
    {
      "source": "gene:EGFR",
      "target": "pathway:PI3K-AKT-mTOR",
      "relation": "activates",
      "properties": {
        "mechanism": "RTK activation leads to PI3K recruitment and PIP3 generation",
        "strength": "strong",
        "conditions": "growth factor stimulation"
      }
    },
    {
      "source": "gene:EGFR",
      "target": "pathway:RAS-MAPK",
      "relation": "activates",
      "properties": {
        "mechanism": "GRB2/SOS recruitment leads to RAS activation",
        "strength": "strong",
        "conditions": "ligand binding and dimerization"
      }
    },
    {
      "source": "drug:Osimertinib",
      "target": "gene:EGFR",
      "relation": "inhibits",
      "properties": {
        "mechanism": "Irreversible covalent binding to Cys797",
        "selectivity": "T790M-selective",
        "ic50": "12 nM (T790M), 1 nM (L858R)"
      }
    },
    {
      "source": "drug:Trastuzumab",
      "target": "gene:HER2",
      "relation": "inhibits",
      "properties": {
        "mechanism": "Extracellular domain binding, prevents dimerization",
        "additional_effects": ["ADCC", "internalization", "downregulation"]
      }
    },
    {
      "source": "gene:KRAS",
      "target": "pathway:RAS-MAPK",
      "relation": "activates",
      "properties": {
        "mechanism": "GTP-bound KRAS activates RAF kinases",
        "mutations": "G12, G13, Q61 hotspots constitutively activate"
      }
    },
    {
      "source": "gene:TP53",
      "target": "pathway:DNA Damage Response",
      "relation": "regulates",
      "properties": {
        "mechanism": "Transcriptional activation of DNA repair genes",
        "outcomes": ["cell cycle arrest", "apoptosis", "senescence"]
      }
    },
    {
      "source": "gene:BRCA1",
      "target": "pathway:Homologous Recombination",
      "relation": "essential_for",
      "properties": {
        "mechanism": "BRCA1-BRCA2-RAD51 complex formation",
        "function": "DNA double-strand break repair"
      }
    },
    {
      "source": "biomarker:PD-L1",
      "target": "disease:Lung Cancer",
      "relation": "predicts_response",
      "properties": {
        "therapy": "Immune checkpoint inhibitors",
        "cutoff": "≥50% TPS for first-line pembrolizumab"
      }
    },
    {
      "source": "biomarker:CEA",
      "target": "disease:Colorectal Cancer",
      "relation": "monitors",
      "properties": {
        "application": "Surveillance and recurrence detection",
        "sensitivity": "70-80% in metastatic disease"
      }
    },
    {
      "source": "pathway:PI3K-AKT-mTOR",
      "target": "disease:Breast Cancer",
      "relation": "drives",
      "properties": {
        "frequency": "PIK3CA mutations in 40% of cases",
        "therapeutic_target": "Alpelisib in HR+ breast cancer"
      }
    },
    {
      "source": "pathway:RAS-MAPK",
      "target": "disease:Colorectal Cancer",
      "relation": "drives",
      "properties": {
        "frequency": "KRAS mutations in 40%, BRAF in 10%",
        "drug_resistance": "Anti-EGFR therapy resistance"
      }
    }
  ]
}